Shaping Biopharma Purification: Phenomenex’s Vision for 2025

Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...

December 12, 2024 | Thursday | Opinion
OmniScience and INmune Bio Join Forces to Transform Global Alzheimer’s Trial Operations with GenAI-Powered Data Platform

OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...

December 05, 2024 | Thursday | News
Gilead Sciences Partners with Tubulis to Develop Next-Generation Antibody-Drug Conjugate for Solid Tumors

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover...

December 04, 2024 | Wednesday | News
Deepull Secures FDA Breakthrough Device Designation for Transformative Bloodstream Infection Test

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced that it has receive...

December 02, 2024 | Monday | News
Eli Lilly Announces Positive Phase 2 Results for Muvalaplin, Oral Treatment for Elevated Lp(a) Levels and Heart Disease Risk

Eli Lilly and Company (NYSE: LLY) announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhi...

November 19, 2024 | Tuesday | News
Alnylam’s Nucresiran Achieves Rapid and Sustained TTR Reduction in Phase 1 Study for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the presentation of new results from its Phase 1 study ...

November 18, 2024 | Monday | News
Agilent Launches Mito-rOCR Assay Kit for Streamlined Mitochondrial Function Analysis

Agilent Technologies Inc. (NYSE: A) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated anal...

November 15, 2024 | Friday | News
EMA CHMP Issues Positive Opinion for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 15, 2024 | Friday | News
Abbisko's Phase 3 Study of Pimicotinib Shows Statistically Significant Efficacy in Treating Tenosynovial Giant Cell Tumor (TGCT)

Abbisko announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically si...

November 12, 2024 | Tuesday | News
BioCity Biopharma Unveils Positive Late-Breaking Results from 2-SUCCEED Trial of SC0062 for IgA Nephropathy at ASN Kidney Week 2024

BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...

November 05, 2024 | Tuesday | News
Abzena Expands Quality Control Testing Capabilities at San Diego Facility, Elevating Biologics Manufacturing and Microbiology Standards

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates announced a significant expansion in their quality control (QC) test...

October 31, 2024 | Thursday | News
Eli Lilly Reports Positive Phase 3b Results for Donanemab, Reducing Amyloid-Related Edema in Alzheimer's Patients

Eli Lilly and Company (NYSE: LLY) announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging...

October 30, 2024 | Wednesday | News
Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria to be Unveiled at ACAAI 2024

Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolle...

October 25, 2024 | Friday | News
Agilent Technologies Introduces Next-Generation InfinityLab LC Series with Innovative Assist Technology, Transforming Lab Automation and Efficiency

Agilent Technologies Inc. (NYSE: A) announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infi...

October 22, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close